[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112022004986A2 - Anticorpos anti-tnfr2 e métodos de uso - Google Patents

Anticorpos anti-tnfr2 e métodos de uso

Info

Publication number
BR112022004986A2
BR112022004986A2 BR112022004986A BR112022004986A BR112022004986A2 BR 112022004986 A2 BR112022004986 A2 BR 112022004986A2 BR 112022004986 A BR112022004986 A BR 112022004986A BR 112022004986 A BR112022004986 A BR 112022004986A BR 112022004986 A2 BR112022004986 A2 BR 112022004986A2
Authority
BR
Brazil
Prior art keywords
methods
tnfr2
antibodies
tnfr2 antibodies
oncological
Prior art date
Application number
BR112022004986A
Other languages
English (en)
Inventor
L Filbert Erin
Krishnan Sushma
Tan Christine
Bahjat Rena
Yang Xiaodong
Alvarado Ryan
Original Assignee
Apexigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apexigen Inc filed Critical Apexigen Inc
Publication of BR112022004986A2 publication Critical patent/BR112022004986A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

ANTICORPOS ANTI-TNFR2 E MÉTODOS DE USO. São fornecidos anticorpos anti-receptor do fator de necrose tumoral 2 (TNFR2) e composições relacionadas, que podem ser usados em qualquer uma de uma variedade de métodos terapêuticos ou diagnósticos, incluindo o tratamento ou diagnóstico de doenças oncológicas, doenças inflamatórias e/ou autoimunes, e outras.
BR112022004986A 2019-09-17 2020-09-11 Anticorpos anti-tnfr2 e métodos de uso BR112022004986A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962901364P 2019-09-17 2019-09-17
US202062985509P 2020-03-05 2020-03-05
US202063047824P 2020-07-02 2020-07-02
US202063058016P 2020-07-29 2020-07-29
PCT/US2020/050515 WO2021055253A2 (en) 2019-09-17 2020-09-11 Anti-tnfr2 antibodies and methods of use

Publications (1)

Publication Number Publication Date
BR112022004986A2 true BR112022004986A2 (pt) 2022-09-06

Family

ID=74884556

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004986A BR112022004986A2 (pt) 2019-09-17 2020-09-11 Anticorpos anti-tnfr2 e métodos de uso

Country Status (11)

Country Link
US (1) US20220372154A1 (pt)
EP (1) EP4031177A4 (pt)
JP (1) JP2022548159A (pt)
KR (1) KR20220071214A (pt)
CN (1) CN114641311A (pt)
AU (1) AU2020348224A1 (pt)
BR (1) BR112022004986A2 (pt)
CA (1) CA3154643A1 (pt)
IL (1) IL291299A (pt)
MX (1) MX2022003249A (pt)
WO (1) WO2021055253A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022267926A1 (zh) * 2021-06-22 2022-12-29 盛禾(中国)生物制药有限公司 一种抗tnfr2抗体及其制备方法和应用
CN117858893A (zh) * 2021-06-30 2024-04-09 盛禾(中国)生物制药有限公司 一种抗tnfr2单域抗体及其制备方法和应用
WO2023281313A1 (en) * 2021-07-07 2023-01-12 Hifibio (Hk) Limited Anti-tnfr2 antibody and uses thereof
WO2023039610A1 (en) * 2021-09-13 2023-03-16 Apexigen, Inc. Antibodies directed against sars-cov-2
CN115925929A (zh) * 2021-09-22 2023-04-07 上海康岱生物医药技术股份有限公司 抗tnfr2单克隆抗体及其应用
CN118317788A (zh) * 2021-12-06 2024-07-09 三优生物医药(上海)有限公司 Tnfr2结合分子及其用途
CN116333123A (zh) * 2021-12-22 2023-06-27 宝船生物医药科技(上海)有限公司 抗tnfr2抗体及其用途
WO2023125483A1 (zh) * 2021-12-28 2023-07-06 山东先声生物制药有限公司 一种抗tnfr2抗体药物组合物
WO2023158431A1 (en) * 2022-02-18 2023-08-24 Adlai Nortye Usa Inc. Anti-tnfr2 antibody and application thereof
WO2024030888A2 (en) * 2022-08-01 2024-02-08 Yale University Tnfr2 antibodies and methods of using the same
CN116381251B (zh) * 2023-03-13 2024-06-25 柏定生物工程(北京)有限公司 一种肿瘤标志物诊断试剂盒及其诊断方法
WO2024201144A1 (en) * 2023-03-31 2024-10-03 Affyxell Therapeutics Co., Ltd. Genetically modified cells comprising a nucleic acid encoding a tnfr2 binding agent and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9821010B2 (en) * 2013-02-07 2017-11-21 The General Hospital Corporation Methods for expansion or depletion of T-regulatory cells
AU2016263198C1 (en) * 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3340999A4 (en) * 2015-08-28 2019-06-12 The General Hospital Corporation TYPE II ANTI-RECEPTOR AGONISTIC ANTIBODIES OF TUMOR NECROSIS FACTOR
WO2017083525A1 (en) * 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
KR20220088515A (ko) * 2016-05-13 2022-06-27 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
US11359027B2 (en) * 2016-06-22 2022-06-14 Universite Paris Est Creteil Val De Marne Prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist
EP3625256A1 (en) * 2017-05-19 2020-03-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2019094559A2 (en) * 2017-11-09 2019-05-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides

Also Published As

Publication number Publication date
JP2022548159A (ja) 2022-11-16
MX2022003249A (es) 2022-06-29
CN114641311A (zh) 2022-06-17
EP4031177A2 (en) 2022-07-27
CA3154643A1 (en) 2021-03-25
WO2021055253A2 (en) 2021-03-25
EP4031177A4 (en) 2023-12-06
IL291299A (en) 2022-05-01
AU2020348224A1 (en) 2022-05-12
KR20220071214A (ko) 2022-05-31
US20220372154A1 (en) 2022-11-24
WO2021055253A3 (en) 2021-04-29
TW202124415A (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
BR112022004986A2 (pt) Anticorpos anti-tnfr2 e métodos de uso
CL2021003289A1 (es) Anticuerpos de unión a cd3. (divisional de solicitud 201900643)
WO2016187220A3 (en) Anti-ror1 antibodies
PH12020551261A1 (en) Il-15 conjugates and uses thereof
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
CL2020001783A1 (es) Composiciones que comprenden microbiota coseleccionada y métodos para su uso
WO2014176128A3 (en) Compositions and methods for the therapy and diagnosis of influenza
EA201790087A1 (ru) Ковалентно связанные диатела, обладающие иммунореактивностью с pd-1 и lag-3, и способы их применения
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
MD3551664T2 (ro) Anticorpi și polipeptide direcționate împotriva CD 127
CL2016000215A1 (es) Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14).
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
BR112022000328A2 (pt) Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
BR122020006918B8 (pt) Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
WO2017181079A3 (en) Methods for monitoring and treating cancer
CY1125104T1 (el) Συνθεσεις φλαγελλινης entrecoccus για χρηση στη θεραπεια
MA39342B2 (fr) Anticorps il -21
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
BR112023020219A2 (pt) Anticorpos anti-il-2r agonistas e métodos de uso
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
MX2021004517A (es) Inhibidores de cinasa de janus 1 triciclicos y composiciones y metodos de los mismos.
Pang et al. Sarcopenia and nonalcoholic fatty liver disease: New evidence for low vitamin D status contributing to the link